Zydus Biologics

Zydus Biologics

Zydus Biologics, a super-specialty focused business of Zydus Lifesciences, is a key pillar of the Company’s research-driven growth strategy. With integrated capabilities across the value chain, from discovery and development to manufacturing, access and commercialisation, it develops and delivers advanced therapies across oncology, nephrology, ophthalmology, other critical areas. Its capabilities span small molecules, biologics and vaccines, with strong expertise in monoclonal antibodies, fusion proteins, antibody drug conjugates and next-generation biosimilars.

Its innovation-led journey is reflected in several industry firsts, including Exemptia, the world’s first biosimilar of Adalimumab, and pioneering vaccines such as VaxiFlu. Supported by a robust pipeline of novel biologics and biosimilars, Zydus Biologics continues to address unmet healthcare needs through differentiated, patient-centric solutions.

The business is also expanding into the global biologics CDMO space through biologics manufacturing facilities in California, US, strengthening capabilities across development, scale up and global supply. This marks an important step in broadening its biologics footprint and enabling wider access to complex therapies worldwide.